Search results
Aug 19, 2022 · Biogen IDEC - Home - Idec Pharma. News Highlights. Transforming Medicine Together. Paul Chinn leads a Biogen Idec team in groundbreaking cancer research. Read how Paul’s work has helped Rick.
Mar 23, 2015 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need – while honoring Biogen’s scientific heritage and legacy as a pioneer in ...
After the merger, Biogen Idec became the 3rd largest Biotechnology company in the world. Following shifts in research core areas, the company has since shortened its name, reverting to simply Biogen.
- 1978; 45 years ago
- Cambridge, Massachusetts, U.S.
- 8,725 (2022)
- US$10.17 billion (2022)
People also ask
What does Biogen Idec do?
What's new at Biogen Idec?
Does Biogen Idec have a culture of Excellence?
Who founded IDEC & Biogen?
Aug 18, 2022 · The BIOGEN IDEC product lineup will be led by two blockbuster drugs, each with annual net sales of more than $1 billion: — AVONEX, for the treatment of patients with relapsing forms of multiple sclerosis.
Biogen Idec is taking steps to build a culture of excellence that values a tighter focus on priorities, faster decision-making, enhanced accountability and improved teamwork. These steps include eliminating management layers, reducing bureaucracy and consolidating overlapping corporate committees.
- Diluted
Aug 18, 2022 · Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis.
Dec 5, 2011 · December 5, 2011 • Corporate. SEOUL, Korea & WESTON, Mass.-- ( BUSINESS WIRE )--Samsung and Biogen Idec (NASDAQ: BIIB) today announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars.
